Pharmacopsychiatry 2012; 45(02): 41-46
DOI: 10.1055/s-0031-1291217
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761® in Alzheimer’s Disease and Vascular Dementia: Results from a Randomised Controlled Trial

R. Ihl
1  Geriatric Psychiatry Centre, Maria-Hilf Hospital Krefeld, Krefeld, Germany
M. Tribanek
2  Clinical Research Department, Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany
N. Bachinskaya
3  Institute of Gerontology, Academy of Medical Sciences, Kiev, Ukraine
for the GOTADAY Study Group› Author Affiliations
Further Information

Publication History

received 29 November 2010
revised 09 July 2011

accepted 18 July 2011

Publication Date:
15 November 2011 (online)



A 24-week randomised controlled trial was conducted to assess the efficacy of a 240 mg once-daily preparation of Ginkgo biloba extract EGb 761® in 404 outpatients≥50 years diagnosed with mild to moderate dementia (SKT 9–23), Alzheimer’s disease (AD) or vascular dementia (VaD), with neuropsychiatric features (NPI total score≥5).


Separate analyses were performed for diagnostic subgroups (probable or possible AD; VaD).


333 patients were diagnosed with AD and 71 with VaD. EGb 761® treatment was superior to placebo with respect to the SKT total score (drug-placebo differences: 1.7 for AD, p<0.001, and 1.4 for VaD, p<0.05) and the NPI total score (drug-placebo differences: 3.1 for AD, p<0.001 and 3.2 for VaD, p<0.05). Significant drug-placebo differences were found for most secondary outcome variables with no major differences between AD and VaD subgroups. Rates of adverse events in EGb 761® and placebo groups were essentially similar.


EGb 761® improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.